The Knowledge Hub

What is the Knowledge Hub?

Explore the VoICE Knowledge Hub—a searchable database featuring the latest peer-reviewed research on immunization benefits, especially in low- and middle-income countries. Browse the Knowledge Hub using a variety of different filters to find vaccine evidence based on country, region, topic, or disease. Click on a tag to find more evidence on a specific area, such as the return on investment of vaccines or impacts of infectious disease outbreaks.


Diseases & Vaccines


WHO Regions


Immunization Terms

Immunization can prevent long-term effects of meningococcal disease, such as hearing loss and psychological problems

A systematic literature review of studies of the long-term effects of invasive meningococcal disease in high-income countries found that children who survived the disease had a greater incidence of hearing loss and psychological problems, including attention-deficit/hyperactivity disorder (ADHD) than control groups or the general population. In addition, they had increased odds of death – one study showed more than a 25% greater mortality rate in this population than did the general public up to 30 years after having the disease.

Strifler L, Morris SK, Dang V et al.. 2016. The health burden of invasive meningococcal disease: a systematic review. Journal of the Pediatric Infectious Diseases Society. 5(4).

Immunization with PCV reduced antibiotic prescriptions for children and slowed antibiotic resistance

In Iceland, a study of all children born over an 11-year period, before and after the introduction of pneumococcal conjugate vaccine (PCV) into the national immunization program, found a 6% decrease in all antibiotic prescriptions for children during their first four years of life and a 22% reduction in prescriptions for otitis media after the vaccine was introduced. Thus, in addition to reducing the burden of pneumococcal disease, PCV may also slow the spread of antibiotic resistance.

Eythorsson E, Sigurdsson S, Hrafnkelsson B. 2018. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study. BMC Infectious Disease. 18(505).